Efficacy and Safety of Switching from Adalimumab Originator to SB5 Biosimilar in Noninfectious Uveitis: Early Clinical Outcomes.
Saved in:
| Title: | Efficacy and Safety of Switching from Adalimumab Originator to SB5 Biosimilar in Noninfectious Uveitis: Early Clinical Outcomes. |
|---|---|
| Authors: | Song, Ji Hun1 (AUTHOR) dreyesong@naver.com, Kim, Chungwoon1 (AUTHOR), Chung, Yoo-Ri1 (AUTHOR), Kim, Hae Rang1 (AUTHOR) |
| Source: | Journal of Clinical Medicine. Nov2025, Vol. 14 Issue 22, p8179. 12p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
